January 10, 2017 5:29pm
… Lower quality’ stocks are depreciating as stocks with the shakiest fundamentals devalue
Still waiting for catalysts to validate their existence …
I say today what others won't, so you can do what others can't!
Pre-open indication’s tally: 2 hit and 2 miss but, my clients made money!
Out and about: Cytori (CYTX) broadened its investigation of the ECCS-50 formulation of Cytori Cell Therapy® to include secondary Raynaud’s phenomenon (RP) beyond scleroderma and MY idea of the 8 dogs of 2017.
Can you afford to miss the insider view … Click here for access and subscribe: http://www.regmedinvestors.com/create-account
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.
U.S. equities were mostly higher in choppy trade on Tuesday, as the NASDAQ notched a fresh record high, while investors prepared for a key news conference from the U.S. president-elect.
The NASDAQ closed UP +20.00 or +0.36% to 5,551.82 and the DOW closed DOWN -31.85 or -0.16% to 19,855.53.
A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:
- The open was positive with an A/DL of 27/13 and 3 flats;
- The mid-day slipped negative with an A/DL of 16/23 and 4 flats;
- The closing bell popped back positive with A/DL of 29/10 and 4 flats;
Henry’omics:
From this morning’s investor’s letter, “looking for clues of pricing sustainability; I’d be watching the cash position and NOT paying the rates to stay in SF for many companies, it’s just another kumbaya!”
- As I had stated, “the sector is NOT focused on accountability ... which explains much of the uncertainty!”
Given that sector breadth has declined, there are many short-term concerns and many more near-term concerns. The near-term concern I have is expectation.
- I maintain that the most important headline for the sector's direction in 2017 pertains to who will be appointed to head the FDA and the alignment of cell and regenerative therapy approval initiatives.
I am NOT ready to put out a forecast as Q4/16 results have NOT been released! There will be – in my view … first a few preambles of the calculated projections.
Indexes, the ebb and flow:
- The iShares Russell 2000 (IWM) indicated a positive +0.01% in the pre- open and closed UP +0.96%.
- The iShares NASDAQ Biotechnology (IBB) indicated a positive +0.33% in the pre-open and closed UP +0.78%
Pre-open indication’s tally: 2 hits (BSTG and PSTI) and 2 miss (CLBS and KITE)
- Biostage (BSTG) closed DOWN -$0.037 – hit;
- Caladrius Biosciences (CLBS0 closed UP +$0.33 – miss;
- Kite Pharma (KITE) closed DOWN -0.25 – miss;
- Pluristem (PSTI) closed UP +$0.15 – hit;
MY idea of the 8 dogs of 2017:
· BioLife Solutions (BLFS)
· Brainstorm Cell Therapeutics (BCLI)
· Capricor (CAPR)
· Cytori (CYTX)
· Fibrocell (FCSC)
· International Stem Cell (ISCO)
· Northwest Bio (NWBO)
· Opexa (OPXA)
Out and about:
Cytori (CYTX) broadened its investigation of the ECCS-50 formulation of Cytori Cell Therapy® to include secondary Raynaud’s phenomenon (RP) beyond scleroderma, a problem that affects over one million patients worldwide.
- Habeo Cell Therapy (formerly ECCS-50) is the new brand name of Cytori Therapeutics’ hand therapy franchise;
- CYTX closed at UP +$0.01 to $1.60 – who can believe ANYTHING they say?
WHAT has happened to all the products and advances of 2015/2016 – GONE, CYTX is just a fraction of what they were and that is dwindling … but, CEO Marc Hedrick still takes a HUGE salary in relation to the share pricing …
Today’s 5 biggest $ gainers included:
- Neuralstem (CUR) +$2.25 after a 1 for 13 reverse split after Monday’s -$0.19;
- ImmunoCellular (NYSEMKT: IMUC) +$2.02;
- Stemline (STML) +$0.75 after Monday’s +$0.30 after Friday’s +$1.55 after Thursday’s -$0.55 after Wednesday’s +$0.50 after last Tuesday’s +0.70;
- Caladrius Biosciences (CLBS) +$0.33;
- Mesoblast (MESO) +0.30;
Today’s 5 biggest $ losers of the session were:
- bluebird bio (BLUE) -$0.55 after Monday’s+$0.60 after Friday’s +$0.70 after Thursday’s -$0.15 after Wednesday’s+$5.80;
- Spark Therapeutics (ONCE) -$0.39 after Monday’s +$4.00 after Friday’s -$0.19 after Thursday’s -$0.81 after Wednesday’s +$5.81 after Tuesday’s +$3.78;
- Cellectis SA (CLLS) -$0.37;
- Kite Pharma (KITE) -$0.25 after Monday’s+$0.75 after Friday’s +$1.56 after Thursday’s +$0.72 after Wednesday’s +$3.03 after Tuesday’s +$1.11;
- Capricor (CAPR) -$0.18;
Flat:
- Cytori (CYTX) at $1.60;
- ReNeuron (RENE.L) at $2.625;
- VistaGen (VTGN) at $3.68;
- Regenxbio (RGNX) at $19.40
The downside trend reflects a pricing trend range of:
- Tuesday’s decliners ranged from -0.28% <BTX> to -6.47% <CAPR> in 14 equities;
- Monday’s decliners ranged from -0.04% <XON> to—4.81% <CUR> in 10 equities;
- Friday’s decliners ranged from -0.12% <MDXG> to-4.82% <CLLS> in 23 equities;
- Thursday’s decliners ranged from -0.22% <BLUE> to -8.96% <ADVM> in 25 equities;
- Wednesday’s decliners ranged from -0.19% <MESO> to -4.09% <VTGN> in 6 equities;
- Last Tuesday’s decliners ranged from +0.24% <BLUE> to +11.67% <CUR> in 30 equities;
The upside shows a pricing trend range of:
- Tuesday’s gainers ranged from +0.41% <OSIR> to +92.82% <IMUC> in 25 equities;
- Monday’s gainers ranged from +0.21% <BLCM> to +15.71% <NWBO> in 29 equities;
- Friday’s gainers ranged from +0.40% <BCLI> to +13.66% <STML> in 18 equities;
- Thursday’s gainers ranged from +0.17% <QURE> to +21.99% <FCSC> in 15 equities;
- Wednesday’s gainers ranged from +0.56% <AXGN> to +13.56 <ADVM> in 34 equities;
- Last Tuesday’s gainers ranged from -0.27% <RGNX> to -5.37% <IMUC> in 12 equities;
The week’s rolls on:
- Tuesday’s 25 gainers followed Monday’s 29, Friday’s 18, Thursday’s 15, Wednesday’s 34, Tuesday’s 30 and last was a Monday’s holiday
- Tuesday’s 14 decliners followed Monday’s 10, Friday’s 23, Thursday’s 25, Wednesday’s 6, Tuesday’s 12 and last Monday’s holiday
Review my fear gauge or the CBOE Volatility Index (VIX):
· Tuesday traded near 11.7;
· Monday traded near 11.6;
· Friday traded near 11.3;
· Thursday traded near 11.7;
· Wednesday traded near 11.9;
· Last Tuesday traded near 12.9;
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
